Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
PLx Pharma downgraded to Perform from Outperform at Oppenheimer » 07:29
08/15/22
08/15
07:29
08/15/22
07:29
PLXP

PLx Pharma

$1.64 /

-0.945 (-36.56%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell downgraded PLx Pharma to Perform from Outperform following the company's Q2 earnings report. Management attributed the Vazalore sales shortfall to the "inflationary macro environment," which the analyst believes has "pressured consumers' willingness to pay a substantial premium for an OTC aspirin product despite efficacy and tolerability advantages." In response, PLx Pharma is further streamlining its sales and marketing plan, including significant personnel reductions, and has engaged a financial advisor to explore and evaluate strategic alternatives. Gershell believes PLx Pharma's "ability to achieve profitability is sharply reduced," and as such, downgraded the stock to Perform and removed his price target.

ShowHide Related Items >><<
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

08/15/22 JMP Securities
PLx Pharma cut to Market Perform at JMP Securities after disappointing Q2 sales
08/15/22 JMP Securities
PLx Pharma downgraded to Market Perform from Outperform at JMP Securities
08/15/22 Oppenheimer
PLx Pharma downgraded to Perform from Outperform at Oppenheimer
03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

Downgrade
PLx Pharma cut to Market Perform at JMP Securities after disappointing Q2 sales » 06:23
08/15/22
08/15
06:23
08/15/22
06:23
PLXP

PLx Pharma

$1.64 /

-0.945 (-36.56%)

JMP Securities analyst…

JMP Securities analyst Jason Butler downgraded PLx Pharma to Market Perform from Outperform. The company's Q2 results missed expectations primarily due to lower-than-expected Vazalore sales as the management pointed to multiple macro headwinds that are impacting the launch, namely as inflationary environment has put pressure on consumer adoption, the analyst tells investors in a research note. Butler adds that while Vazalore sales estimates support upside from the stock's current valuation, the current strategic review process also announced by PLx "places substantial uncertainty" on realizing these projections.

ShowHide Related Items >><<
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

08/15/22 JMP Securities
PLx Pharma downgraded to Market Perform from Outperform at JMP Securities
08/15/22 Oppenheimer
PLx Pharma downgraded to Perform from Outperform at Oppenheimer
03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

Downgrade
PLx Pharma downgraded to Market Perform from Outperform at JMP Securities » 05:28
08/15/22
08/15
05:28
08/15/22
05:28
PLXP

PLx Pharma

$1.64 /

-0.945 (-36.56%)

JMP Securities analyst…

JMP Securities analyst Jason Butler downgraded PLx Pharma to Market Perform from Outperform.

ShowHide Related Items >><<
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

08/15/22 Oppenheimer
PLx Pharma downgraded to Perform from Outperform at Oppenheimer
03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

Downgrade
PLx Pharma downgraded to Perform from Outperform at Oppenheimer » 05:26
08/15/22
08/15
05:26
08/15/22
05:26
PLXP

PLx Pharma

$1.64 /

-0.945 (-36.56%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell downgraded PLx Pharma to Perform from Outperform.

ShowHide Related Items >><<
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

PLXP PLx Pharma
$1.64 /

-0.945 (-36.56%)

On The Fly
Fly Intel: Pre-market Movers » 08:59
08/12/22
08/12
08:59
08/12/22
08:59
UBX

Unity Biotechnology

$0.85 /

-0.1199 (-12.36%)

, APLT

Applied Therapeutics

$1.31 /

+0.09 (+7.38%)

, RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

, AIRS

AirSculpt Technologies

$8.85 /

-0.45 (-4.84%)

, PAYO

Payoneer Global

$5.68 /

+0.045 (+0.80%)

, TOST

Toast

$18.12 /

-0.33 (-1.79%)

, RIVN

Rivian Automotive

$38.91 /

+1.475 (+3.94%)

, LPTX

Leap Therapeutics

$1.32 /

+0.15 (+12.82%)

, PLXP

PLx Pharma

$2.59 /

+0.015 (+0.58%)

, SPB

Spectrum Brands

$70.37 /

+0.75 (+1.08%)

, CODX

Co-Diagnostics

$6.44 /

-0.195 (-2.94%)

, ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

, LAW

CS Disco

$28.96 /

+0.39 (+1.37%)

, ELF

e.l.f. Beauty

$36.44 /

-0.02 (-0.05%)

Check out this morning's…

ShowHide Related Items >><<
UBX Unity Biotechnology
$0.85 /

-0.1199 (-12.36%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

SPB Spectrum Brands
$70.37 /

+0.75 (+1.08%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

UBX Unity Biotechnology
$0.85 /

-0.1199 (-12.36%)

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

06/16/22 Morgan Stanley
AirSculpt downgraded to Equal Weight from Overweight at Morgan Stanley
02/09/22 Piper Sandler
Piper Sandler bullish into AirSculpt Technologies Q4 results
01/25/22 Piper Sandler
AirSculpt Technologies transferred with Overweight at Piper Sandler
12/21/21 Piper Sandler
AirSculpt should could double from current levels, says Piper Sandler
PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

07/14/22 Goldman Sachs
Payoneer Global upgraded to Buy from Neutral at Goldman Sachs
05/13/22 Northland
Payoneer Global price target lowered to $9 from $14 at Northland
05/13/22 Citi
Payoneer Global price target raised to $7.50 from $6.50 at Citi
03/04/22 Needham
Payoneer Global price target lowered to $7 from $13 at Needham
TOST Toast
$18.12 /

-0.33 (-1.79%)

08/12/22 Needham
Toast price target raised to $27 from $21 at Needham
08/12/22 KeyBanc
Toast price target raised to $25 from $18 at KeyBanc
05/17/22 Mizuho
Toast price target lowered to $18 from $19 at Mizuho
05/13/22 Needham
Toast price target lowered to $21 from $38 at Needham
RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

08/12/22 DA Davidson
Rivian Automotive price target raised to $27 from $24 at DA Davidson
08/12/22 Morgan Stanley
Rivian Automotive's liqudity can last through most of FY23, says Morgan Stanley
08/12/22 Mizuho
Rivian Automotive price target lowered to $65 from $70 at Mizuho
07/18/22 Deutsche Bank
Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank
LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

06/06/22 Piper Sandler
Piper says Leap's DKN-01 combo showed 'interesting early signal of activity'
05/27/22 Piper Sandler
Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
01/23/22 Piper Sandler
Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
SPB Spectrum Brands
$70.37 /

+0.75 (+1.08%)

07/18/22 Oppenheimer
Spectrum Brands price target lowered to $95 from $125 at Oppenheimer
07/18/22 UBS
Spectrum Brands price target lowered to $109 from $119 at UBS
07/18/22 Wells Fargo
Spectrum Brands price target lowered to $100 from $122 at Wells Fargo
07/13/22 Raymond James
Spectrum Brands initiated with a Market Perform at Raymond James
CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

08/12/22 Sidoti
Co-Diagnostics downgraded to Neutral from Buy at Sidoti
05/16/22 H.C. Wainwright
Co-Diagnostics price target lowered to $12 from $15 at H.C. Wainwright
12/29/21 Sidoti
Sidoti starts Co-Diagnostics at Buy, sees opportunities opened by COVID-19 test
12/29/21 Sidoti
Co-Diagnostics initiated with a Buy at Sidoti
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/12/22 Piper Sandler
Piper a buyer of Illumina weakness ahead of Genomics Forum
08/12/22 Canaccord
Illumina price target lowered to $380 from $450 at Canaccord
08/12/22 Stifel
Illumina price target lowered to $300 from $480 at Stifel
08/12/22 Citi
Illumina price target lowered to $200 from $220 at Citi
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

08/12/22 Canaccord
CS Disco downgraded to Hold at Canaccord as estimates get reset
08/12/22 Stifel
CS Disco price target lowered to $30 from $40 at Stifel
08/12/22 BofA
CS Disco downgraded to Neutral from Buy at BofA
08/12/22 Canaccord
CS Disco downgraded to Hold from Buy at Canaccord
ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform at Cowen on valuation
08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform from Outperform at Cowen
08/04/22 Truist
e.l.f. Beauty price target raised to $40 from $35 at Truist
07/21/22 JPMorgan
e.l.f. Beauty price target raised to $35 from $30 at JPMorgan
UBX Unity Biotechnology
$0.85 /

-0.1199 (-12.36%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

SPB Spectrum Brands
$70.37 /

+0.75 (+1.08%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

  • 23
    Jun
  • 10
    Nov
  • 29
    Oct
  • 22
    Sep
  • 22
    Sep
  • 15
    Sep
RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

Hot Stocks
PLx Pharma announces survey data on VAZALORE 81 mg » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
PLXP

PLx Pharma

$2.59 /

+0.015 (+0.58%)

PLx Pharma, with its lead…

PLx Pharma, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules, announced positive findings from its initial VAZALORE 81 mg Patient Experience Survey. Between April and June 2022, PLx Pharma distributed Patient Experience Survey kits to high-volume cardiology offices nationwide, where physicians are actively recommending VAZALORE 81 mg for the secondary prevention of cardiovascular disease. The kits included a VAZALORE 81 mg product sample, product literature and a high-value coupon. Physicians provided the survey kits to patients they deemed appropriate for daily aspirin use. Results from 130 respondents through August 3, 2022, showed that 95% of patients are satisfied with VAZALORE and 90% intend to purchase the product. Key Findings: 97% felt they are doing all they can to help support their heart health; 96% felt no issues with their stomach when taking, either with or without food; 96% are likely to remember to take VAZALORE every day; 98% said VAZALORE is easy to swallow; 95% satisfied with VAZALORE as their aspirin therapy choice; 90% intend to purchase. "These real-world results, gathered from patients who have taken VAZALORE 81 mg, are very promising and indicative of the potential uptake of the brand and its importance in the treatment of secondary prevention of cardiovascular events for millions of patients," said Natasha Giordano, President & CEO of PLx Pharma.

ShowHide Related Items >><<
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

Earnings
PLx Pharma reports Q2 EPS (52c), consensus (56c) » 06:55
08/12/22
08/12
06:55
08/12/22
06:55
PLXP

PLx Pharma

$2.59 /

+0.015 (+0.58%)

Reports Q2 revenue $0.5M,…

Reports Q2 revenue $0.5M, consensus $3.53M. "A key priority for us in Q2 was implementing our refined marketing plan, putting greater emphasis on more cost efficient nonpersonal promotion, such as virtual and digital communications," said CEO Natasha Giordano. "We, like many companies, experienced a tough inflationary environment this quarter, marked by a shift in consumer spending and higher retail inventories...We have moved quickly to further streamline our sales and marketing plan, including significantly reducing our Cardiovascular Care Specialist team. Despite these challenges, we remain as confident as ever in VAZALORE's potential to transform the standard of aspirin therapy for secondary prevention of cardiovascular events and to reinvent aspirin for pain relief...However, given the current market dynamics, we believe the uptake of VAZALORE could be maximized through a larger commercial organization with resources to drive a more robust commercial plan". Executive Chairman of the Board Michael Valentino, said, "Another strategic priority of the quarter was evaluating options to bring in new sources of non-dilutive capital, including business development activities...management engaged a financial advisor to commence a formal process to evaluate strategic alternatives to enhance stockholder value."

ShowHide Related Items >><<
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

Over a quarter ago
Hot Stocks
PLx Pharma showcases VAZALORE at SCAI annual meeting » 08:32
05/20/22
05/20
08:32
05/20/22
08:32
PLXP

PLx Pharma

$2.97 /

+0.195 (+7.03%)

PLx Pharma announced that…

PLx Pharma announced that it is participating in the annual meeting of the Society for Cardiovascular Angiography and Interventions, SCAI, during May 19 - 22, 2022 in Atlanta, GA. Separately, the Company acknowledged the recent publication of an article in the journal Healio examining the potential of VAZALORE as an innovative approach to aspirin delivery that is designed to provide optimal absorption while helping to protect against local gastrointestinal injury. In the article titled, "Some Needs Unmet in Secondary CVD Prevention Despite Aspirin Use; New Agent May Have A Role," author C. Michael Gibson discusses the attributes of aspirin that make it an effective antiplatelet agent but also pose significant risk of upper GI injury, as well as the limitations of low-dose enteric-coated aspirin. Arguing there is a need for innovation in aspirin treatment, Dr. Gibson provides a review of a number of studies showing VAZALORE has the potential to fill that unmet need by offering optimal absorption while its unique delivery system was designed to help protect the gastroduodenal lining.

ShowHide Related Items >><<
PLXP PLx Pharma
$2.97 /

+0.195 (+7.03%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$2.97 /

+0.195 (+7.03%)

Earnings
PLx Pharma reports Q1 non-GAAP EPS (66c), consensus (72c) » 06:52
05/13/22
05/13
06:52
05/13/22
06:52
PLXP

PLx Pharma

$2.04 /

-0.31 (-13.19%)

Reports Q1 revenue $2.1M,…

Reports Q1 revenue $2.1M, consensus $2.53M. As of March 31, the company had $52.5M in cash and cash equivalents, $0.7M in accounts receivable and zero debt on its balance sheet. "Our solid base of VAZALORE users continues to grow, and feedback from consumers and healthcare professionals is overwhelmingly positive," said CEO Natasha Giordano. "We continuously evaluate the feedback, along with market research and other data, and have refined our marketing efforts. We are intensifying our focus to more strongly differentiate VAZALORE from the limitations of other aspirins. VAZALORE provides fast, predictable absorption and was designed to help protect the gastroduodenal lining. We are executing enhanced messaging and some unique programs to increase trial and conversion among a broader community of consumers and healthcare professionals."

ShowHide Related Items >><<
PLXP PLx Pharma
$2.04 /

-0.31 (-13.19%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$2.04 /

-0.31 (-13.19%)

Recommendations
BWS drops coverage of PLx Pharma, says off Amazon again » 09:20
03/15/22
03/15
09:20
03/15/22
09:20
PLXP

PLx Pharma

$3.60 /

-0.455 (-11.23%)

, AMZN

Amazon.com

$2,836.00 /

-73.045 (-2.51%)

BWS Financial analyst…

BWS Financial analyst Hamed Khorsand dropped coverage of PLx Pharma (PLXP) saying the company's Q4 results show it will take longer than expected to achieve a sales ramps. PLx is once again offline on Amazon.com (AMZN) even though management went out of their way to mention the company's presence on the site four times during the earnings call, Khorsand tells investors in a research note. The analyst believes the "on again off again" with Amazon could have lasting effects on PLx's sales ramp. He's dropping coverage with a loss on the recommendation.

ShowHide Related Items >><<
PLXP PLx Pharma
$3.60 /

-0.455 (-11.23%)

AMZN Amazon.com
$2,836.00 /

-73.045 (-2.51%)

PLXP PLx Pharma
$3.60 /

-0.455 (-11.23%)

12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
09/21/21 BWS Financial
PLx Pharma initiated with a Buy at BWS Financial
AMZN Amazon.com
$2,836.00 /

-73.045 (-2.51%)

03/10/22 Deutsche Bank
Amazon.com initiated with a Buy at Deutsche Bank
03/10/22 Morgan Stanley
Amazon split and buyback 'an important, positive signal,' says Morgan Stanley
03/10/22 Wells Fargo
Amazon share repurchase evidence of focus on profitability, says Wells Fargo
03/10/22 Morgan Stanley
Morgan Stanley constructive on Affirm's long-term opportunity after meetings
PLXP PLx Pharma
$3.60 /

-0.455 (-11.23%)

AMZN Amazon.com
$2,836.00 /

-73.045 (-2.51%)

AMZN Amazon.com
$2,836.00 /

-73.045 (-2.51%)

AMZN Amazon.com
$2,836.00 /

-73.045 (-2.51%)

AMZN Amazon.com
$2,836.00 /

-73.045 (-2.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.